best of the rest

These Houston startups and companies clock in as the top employers in the U.S.

MD Anderson Cancer Center is a top place to work in the U.S. and Texas. Photo by F. Carter Smith/courtesy of MD Anderson

Whose boss is doing something right in Houston? Forbes set out to find out.

New rankings from Forbes identified the top employers in Houston and beyond, and that included both bigger companies and the country’s best startup employers. In Houston, the startups ranked as top employers are:

No. 120 — Imbuit
No. 310 — Code Ninjas (Pearland)
No. 353 — Axiom Space
No. 462 — Liongard

When it comes to more traditional businesses, Dr. Pete Pisters, CEO of MD Anderson Cancer Center, continues his reign. He was named a top boss in 2021. Now, the cancer treatment facility/research center he leads has been named one of the best employers in a new report.

MD Anderson Cancer Center ranked No. 10 among the country’s best large employers in the country. Staffing some 22,000 employees, the world-renowned cancer center also landed at No. 25 in Forbes list of America's Best Employers in 2021.

Other Houston-area companies on the list include: Houston Methodist (No. 37), Waste Management (No. 245), Sysco (No. 314), Shell Oil (no. 361), Halliburton (No. 389), Schlumberger (No. 403), ExxonMobil (No. 440), and BP (No. 487).

Other Texas employers ranked among the best large employers in the U.S. are:

  • No. 10 — MD Anderson Cancer Center, Houston
  • No. 37 — Houston Methodist, Houston
  • No. 38 — H-E-B, San Antonio
  • No. 135 — USAA, San Antonio
  • No. 140 — Keller Williams Realty, Austin
  • No. 143 — Dell Technologies, Round Rock
  • No. 214 — Texas Tech University, Lubbock
  • No. 245 — Waste Management, Houston
  • No. 279 — University of Texas at Austin
  • No. 314 — Sysco, Houston
  • No. 318 — Daikin Industries, Waller (North American operations hub for manufacturing, marketing, research, R&D, and customer support)
  • No. 324 — Whole Foods Market, Austin
  • No. 361 — Shell Oil, Houston
  • No. 389 — Halliburton, Houston
  • No. 403 — Schlumberger, Houston
  • No. 440 — ExxonMobil, Houston
  • No. 487 — BP, Houston (North American headquarters)

Elsewhere in Texas, Dallas reigns as the capital of Texas when it comes to the best big and small employers, according to Forbes, which put University of Texas Southwestern Medical Center in Dallas at No. 9 among the country’s best large employers in the country and Dallas-based life insurance platform Bestow at No. 16 among the country’s best startup employers.

UT Southwestern isn’t the only Dallas-Fort Worth employer to pop up on the Forbes list of the best large employers. Richardson-based software company RealPage sits at No. 49; Dallas-based Southwest Airlines, No. 56; Plano-based Toyota North America, No. 253; Plano-based Cinemark, No. 370; Dallas-based Jacobs, No. 375; Dallas-based Topgolf, No. 394; Dallas-based Primoris Services, No. 399; Irving-based Fluor, No. 422; Dallas-based CBRE, No. 423; Irving-based McKesson, No. 429; Fort Worth-based American Airlines, No. 446; and Plano-based Keurig Dr Pepper, No. 483.

Dallas-based software company Slync.io, holding the No. 290 spot for best startups.

What follows are the other Texas employers ranked among the best startup employers in the country.

Austin

No. 104 — Apty
No. 121 — Homeward
No. 169 — SparkCognition
No. 186 — Outdoor Voices
No. 255 — Outdoorsy
No. 323 — ICON
No. 324 — The Zebra
No. 330 — TrustRadius
No. 335 — Innovetive Petcare (Cedar Park)
No. 387 — AlertMedia
No. 400 — Iris Telehealth
No. 410 — Wheel
No. 455 — Billd
No. 460 — Aceable
No. 470 — Shipwell

Forbes teamed up with data and research company Statista to develop the rankings of the best large employers and best startup employers.

Trending News

 
 

Promoted

A research team housed out of the newly launched Rice Biotech Launch Pad received funding to scale tech that could slash cancer deaths in half. Photo via Rice University

A research funding agency has deployed capital into a team at Rice University that's working to develop a technology that could cut cancer-related deaths in half.

Rice researchers received $45 million from the National Institutes of Health's Advanced Research Projects Agency for Health, or ARPA-H, to scale up development of a sense-and-respond implant technology. Rice bioengineer Omid Veiseh leads the team developing the technology as principal investigator.

“Instead of tethering patients to hospital beds, IV bags and external monitors, we’ll use a minimally invasive procedure to implant a small device that continuously monitors their cancer and adjusts their immunotherapy dose in real time,” he says in a news release. “This kind of ‘closed-loop therapy’ has been used for managing diabetes, where you have a glucose monitor that continuously talks to an insulin pump. But for cancer immunotherapy, it’s revolutionary.”

Joining Veiseh on the 19-person research project named THOR, which stands for “targeted hybrid oncotherapeutic regulation,” is Amir Jazaeri, co-PI and professor of gynecologic oncology at the University of Texas MD Anderson Cancer Center. The device they are developing is called HAMMR, or hybrid advanced molecular manufacturing regulator.

“Cancer cells are continually evolving and adapting to therapy. However, currently available diagnostic tools, including radiologic tests, blood assays and biopsies, provide very infrequent and limited snapshots of this dynamic process," Jazaeri adds. "As a result, today’s therapies treat cancer as if it were a static disease. We believe THOR could transform the status quo by providing real-time data from the tumor environment that can in turn guide more effective and tumor-informed novel therapies.”

With a national team of engineers, physicians, and experts across synthetic biology, materials science, immunology, oncology, and more, the team will receive its funding through the Rice Biotech Launch Pad, a newly launched initiative led by Veiseh that exists to help life-saving medical innovation scale quickly.

"Rice is proud to be the recipient of the second major funding award from the ARPA-H, a new funding agency established last year to support research that catalyzes health breakthroughs," Rice President Reginald DesRoches says. "The research Rice bioengineer Omid Veiseh is doing in leading this team is truly groundbreaking and could potentially save hundreds of thousands of lives each year. This is the type of research that makes a significant impact on the world.”

The initial focus of the technology will be on ovarian cancer, and this funding agreement includes a first-phase clinical trial of HAMMR for the treatment of recurrent ovarian cancer that's expected to take place in the fourth year of THOR’s multi-year project.

“The technology is broadly applicable for peritoneal cancers that affect the pancreas, liver, lungs and other organs,” Veiseh says. “The first clinical trial will focus on refractory recurrent ovarian cancer, and the benefit of that is that we have an ongoing trial for ovarian cancer with our encapsulated cytokine ‘drug factory’ technology. We'll be able to build on that experience. We have already demonstrated a unique model to go from concept to clinical trial within five years, and HAMMR is the next iteration of that approach.”

Trending News

 
 

Promoted